vs
NRX Pharmaceuticals, Inc.（NRXP）与Glimpse Group, Inc.（VRAR）财务数据对比。点击上方公司名可切换其他公司
Glimpse Group, Inc.的季度营收约是NRX Pharmaceuticals, Inc.的1.3倍（$1.3M vs $983.0K），NRX Pharmaceuticals, Inc.净利率更高（36.7% vs -94.3%，领先131.0%）
NRX Pharmaceuticals是一家处于临床阶段的生物制药企业，专注于开发针对中枢神经系统疾病的创新疗法，覆盖罕见神经精神类适应症，核心市场以美国为主，核心在研产品面向有未满足医疗需求的重度情绪与创伤相关疾病患者。
Glimpse Group是一家专注于虚拟现实（VR）和增强现实（AR）技术研发的沉浸式科技企业，服务覆盖企业、教育、医疗、消费娱乐等多个领域，为北美及全球客户提供定制化沉浸式体验、软件平台及交互工具。
NRXP vs VRAR — 直观对比
营收规模更大
VRAR
是对方的1.3倍
$983.0K
净利率更高
NRXP
高出131.0%
-94.3%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $983.0K | $1.3M |
| 净利润 | $361.0K | $-1.2M |
| 毛利率 | — | 60.7% |
| 营业利润率 | — | -97.1% |
| 净利率 | 36.7% | -94.3% |
| 营收同比 | — | -59.0% |
| 净利润同比 | 104.0% | -4837.1% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRXPVRAR
| Q4 25 | $983.0K | $1.3M | ||
| Q3 25 | $242.0K | $1.4M | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q3 24 | $0 | — |
净利润NRXPVRAR
| Q4 25 | $361.0K | $-1.2M | ||
| Q3 25 | $-5.9M | $-1.0M | ||
| Q2 25 | $-17.6M | — | ||
| Q1 25 | $-5.5M | — | ||
| Q3 24 | $-1.6M | — |
毛利率NRXPVRAR
| Q4 25 | — | 60.7% | ||
| Q3 25 | 59.9% | 72.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
营业利润率NRXPVRAR
| Q4 25 | — | -97.1% | ||
| Q3 25 | -1662.8% | -95.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
净利率NRXPVRAR
| Q4 25 | 36.7% | -94.3% | ||
| Q3 25 | -2433.9% | -73.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
每股收益（稀释后）NRXPVRAR
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.8M | $3.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-15.9M | $15.3M |
| 总资产 | $13.0M | $16.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRXPVRAR
| Q4 25 | $7.8M | $3.3M | ||
| Q3 25 | $7.2M | $5.6M | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | $5.5M | — | ||
| Q3 24 | $1.6M | — |
股东权益NRXPVRAR
| Q4 25 | $-15.9M | $15.3M | ||
| Q3 25 | $-25.8M | $16.2M | ||
| Q2 25 | $-35.6M | — | ||
| Q1 25 | $-25.2M | — | ||
| Q3 24 | $-18.8M | — |
总资产NRXPVRAR
| Q4 25 | $13.0M | $16.0M | ||
| Q3 25 | $15.0M | $18.3M | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $7.6M | — | ||
| Q3 24 | $4.5M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.7M | $-739.2K |
| 自由现金流经营现金流 - 资本支出 | — | $-747.3K |
| 自由现金流率自由现金流/营收 | — | -57.5% |
| 资本支出强度资本支出/营收 | — | 0.6% |
| 现金转化率经营现金流/净利润 | -10.29× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流NRXPVRAR
| Q4 25 | $-3.7M | $-739.2K | ||
| Q3 25 | $-2.9M | $-1.3M | ||
| Q2 25 | $-4.0M | — | ||
| Q1 25 | $-3.5M | — | ||
| Q3 24 | $-2.3M | — |
自由现金流NRXPVRAR
| Q4 25 | — | $-747.3K | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
自由现金流率NRXPVRAR
| Q4 25 | — | -57.5% | ||
| Q3 25 | — | -92.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
资本支出强度NRXPVRAR
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
现金转化率NRXPVRAR
| Q4 25 | -10.29× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRXP
暂无分部数据
VRAR
| Software Services | $1.2M | 90% |
| Other | $124.4K | 10% |
